A mouse study found that a popular anti-aging drug combination associated with longevity research caused severe loss of myelin in the brain.
Myelin sheaths insulate nerve fibers, and damage can impair signaling and contribute to neurological dysfunction.
Researchers observed the effect after administering the combination widely discussed in lifespan extension communities, raising questions about off-label human use.
Authors emphasized that rodent findings require careful evaluation before drawing conclusions about clinical safety in people.
Regulatory and medical experts said the results underscore the need for rigorous trials before promoting experimental regimens as wellness products.
Longevity research communities have debated off-label use of drug combinations promoted online without peer-reviewed safety validation in humans.
Myelin loss in the mouse study appeared in brain regions associated with cognitive and motor coordination, prompting neurologist review of the data.
Authors recommended against self-experimentation until controlled human trials establish whether similar effects occur at therapeutic dose ranges.
Institutional review boards would scrutinize any proposal to translate the longevity drug combination from mouse studies into human trials.
Neuroscience journals requested additional histological imaging to confirm the extent and reversibility of myelin loss observed.
Bioethicists urged caution against consumer promotion of the longevity drug combination until human safety data address the myelin findings reported in mice.
Research found that a widely-studied longevity drug combination caused severe loss of myelin in mouse brains raising safety concerns for human use.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/